PKC412 - A protein kinase inhibitor with a broad therapeutic potential

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 17-28

  Fabbro, Doriano ^a   Ruetz, Stephan ^a   Bodis, Stephan ^b   Pruschy, Martin ^b   Csermak, Katalin ^a   Man, Anthony ^a   Campochiaro, Peter ^c   Wood, Jeanette ^a   O'Reilly, Terence ^a   Meyer, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenic in vitro and in vivo; In vitro antiproliferation; In vivo antitumor; Protein kinase C subtypes; Protein kinase inhibitors; Vascular endothelial growth factor receptor

Indexed keywords

DOXORUBICIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; STAUROSPORINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE G2 PHASE; CELL LINE; DRUG POTENTIATION; IONIZING RADIATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD PROTEINS; CELL CYCLE; CLINICAL TRIALS, PHASE I; ENZYME INHIBITORS; HUMANS; MICE; NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE C; STAUROSPORINE; TUMOR CELLS, CULTURED;

MURINAE;

EID: 18844478996     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Adamis A.P., Shima D.T., Yeo K.T., Brown L.F., Berse B., D'Amore P.A.F. (1993) Synthesis and expression of vascular permeability factor/vascular endothelial growth factor by human retinal sigment epithelial cells. Biochemical and Biophysical Research Communications, 193, 631.
2. Aiello L.P., Avery R.L., Arragg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. (1994) Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine, 331, 1480.
3. Viello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E.H. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric protein. Proceedings of the National Academy of Sciences. USA, 92, 10457.
4. Aiello L.P., Bursell S.-E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E., King G.L. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform selective inhibitor. Diabetes, 46, 1473.
5. Akiyama T., Shimizu M., Okabe M., Tamaoki T., Akinaga S. (1999) Differential effects of UCN-O1, staurosporine and CGP 41251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Anticancer-Drugs, 10, 67.
6. Alkan S., Rutschmann S., Grogg D., Erb P. (1993) Effect of a new protein kinase C inhibitor PKC412 on T cell functions: inhibition of growth and target cell killing. Cellular Immunology, 150, 137.
7. Andrejauskas-Buchdunger E., Regenass U. (1992) Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C mediated signal transduction pathways by the staurosporine derivative PKC412. Cancer Research, 52, 5353.
8. Asaoka Y., Nakamura S., Yoshida K., Nishizuka Y (1992) Protein kinase C, calcium and phospho-lipid degradation. Trends in the Biological Sciences, 17, 414.
9. Begemann M., Kashimawo S.A., Choi Y.A., Kim S., Christiansen K.M., Duigou G., Müller M., Schieren I., Ghosh S., Fabbro D., Lampen N.M., Schiff P.B., Bruce J.N., Weinstein I.B. (1996) Inhbition of the growth of glioblastoma by PKC412, an inhibitor of protein kinase C and by a phorbol ester tumor promoter. Clinical Cancer Research, 2, 1017.
10. Begemann M., Kashimawo S.A., Heitjan D.F., Schiff P.B., Bruce J.N., Weinstein B. (1998) Treatment of human glioblastoma cells with the staurosporine derivative PKC412 inhibits cdc2 and ckd2 kinase activity and increases radiation sensititivity. Anticancer Research, 18, 2275.
11. Beltram J.P., Fan D., Fidler I.J., O'Brian A.C. (1997) Chemosensitization of cancer cells by the saturosporine derivative PKC412 in association with decreased P-glycoprotein phosphorylation. Biochemical Pharmacology, 53, 245.
12. Blobe G.C., Sachs C.W., Khan W.A., Fabbro D., Stabel S., Wetsel W., Obeid L.M., Fine R.L., Hannun Y.A. (1993) Selective regulation of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Journal of Biological Chemistry, 268, 658.
13. Blobe G.C., Obeid L.M., Hannun Y.A. (1994) Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Review, 13, 411.
14. Borner C., Fabbro D. (1992) Protein kinase C and cellular transformation. In Protein Kinase C: Current Concepts find Future Perspectives. Lester D., Epand R. (eds), p. 297. Ellis Horwood Series in Biochemistry and Biotechnology: Chichester.
15. Bourne R.H. (1997) How receptors talk to trimeric G proteins. Current Opinion in Cell Biology, 9, 134.
16. Danis R.P., Bingaman D.I.P., Jirousek M., Yang Y. (1998) Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCA inhibition with LY 333531. Investigations in Ophthalmology and Visual Science, 39, 171.
17. Dekker L.V., Parker P.J. (1994) Protein kinase C a question of specificity. Trends in the Biological Sciences, 19, 73.
18. Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., Berse B., Dvorak, H.F. (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. Journal of Experimental Medicine, 180, 1141.
19. Dietel M. (1993) Meeting report: Second International Symposium on cytostatic drug resistance. Cancer Research, 53, 2683.
20. Downward J. (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Current Opinion in Cell Biology, 10, 262.
21. Egan S.E., Weinberg R.A. (1993) The pathway to signal achievement. Nature, 365, 781; (1999) Current Opinion in Cell Biology, 11, 159.
22. Egan S.E., Weinberg R.A. (1993) The pathway to signal achievement. Nature, 365, 781; (1999) Current Opinion in Cell Biology, 11, 159.
23. Fabbro D., Buchdunger E., Wood J., Mestan J., Hofmann F., Ferrari S., Mett H., O'Reilly T., Meyer T. (1999) CGP 41251 a protein kinase inhibitor with potential as an anti-cancer agent. Pharmacology and Therapeutics, 82, 293.
24. Fava R.A., Olsen N.J., Spencer-Green G., Yeo K.T., Yeo T.K., Berse B., Jackman R.W., Senger D.R., Dvorak H.F., Brown L. F. (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. Journal of Experimental Medicine, 180, 341.
25. Ferrara N., Davis-Smyth T. (1997) The biology of vascular endothelial growth factor. Endocrine Review, 18, 4.
26. Ferrara N., Chen H., Davis-Smith T., Gerber H.P., Nguyen T.H., Peers D., Chisholm V., Hillan K.J., Schwall R.H. (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine, 4, 336.
27. Folkman J., Shing Y. (1992) Angiogenesis. Journal of Biological Chemistry, 267, 10931.
28. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1, 27.
29. Fredericks W.J., Chen Y.F., Baker R.M. (1991) Immunoblot detection of P-glycoprotein in human tumours and cell lines. In Molecular and Clinical Advances in Anticancer Drug Resistance. Ozols R.F. (ed.), p. 121. Kluwer Academic Publishers: Boston, MA.
30. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Yamura T., Sasaki Y., Tanigawara Y., Kuwabara T., Kobayashi S. (1998) Unpredicted clinical pharmacokinetics of UCN-01 caused by the specific binding to human alpha-acid glycoprotein. In Scientific Proceedings, 89th Annual Meeting of the American Association of Cancer Research, Vol. 39, Abstract 2482.
31. Geiges D., Meyer T., Marte B., Vanek M., Weissgerber G., Stabel S., Pfeilschifter J., Fabbro D., Huwiler A. (1996) Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta and eta by tumor-promoting and nontumor-promoting agents. Biochemical Pharmacology, 53, 865.
32. Gottesman M.M. (1993) How cancer cells evade chemotherapy: Sixteenth Richard and Linda Rosenthal Foundation Award lecture. Cancer Research, 53, 747.
33. Hackel P.O., Zwick E., Prenzel N., Ullrich A. (1999) Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opinion in Cell Biology, 11, 184.
34. Hammes H.P., Lin J., Bretzel R.G., Brownlee M., Breier G. (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes, 47, 401.
35. Hill D.L., Lin T.-H., Duncan K.L.K., Smith A.C. (1998) Binding of UCN-01 to plasma proteins of human, rats and dogs. In Scientific Proceedings, 89th Annual Meeting of the American Association of Cancer Research, Vol. 39, Abstract 2483.
36. Houslay M.D. (1991) 'Crosstalk': a pivotal role for protein kinase C in mediating relationship between signal transduction pathways. European Journal of Biochemistry, 195, 9.
37. Ikegami Y., Yano S., Nakao K. (1996a) Antitumor effect of PKC412, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Japanese Journal of Pharmacology, 70, 65.
38. Ikegami Y., Yano S., Nakao K. (1996b) Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneimittel-Forschung, 46, 201.
39. Inoguchi T., Battan R., Handier R., Sportsman J.R., Heath W., King G.L. (1992) Preferential elevation of protein kinase C isoform beta2 and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proceedings of the National Academy of Sciences, USA, 89, 11059.
40. Ip Y.T., Davis R.J. (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)- from inflammation to development. Current Opinion in Cell Biology, 10, 205.
41. Killion J.J., Beltran P., O'Brian C.A., Yoon S.-S., Fan D., Wilson M.R., Fidler I.J. (1995) The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, PKC412. Oncology Research, 1, 453.
42. Korpelainen E.I., Alitalo K. (1998) Signalling angiogenesis and lympangiogeneis. Current Opinion in Cell Biology, 10, 159.
43. Koya D., King G.L. (1998) Protein kinase C activation and the development of diabetic complications. Diabetes, 47, 859.
44. Lansiaux A., Fabbro D., Meyer T., Hamy F., Bailly C. (1999) Le CGP 41251. Bulletin of Cancer, 86, 614.
45. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. (1999) Signaling through phophoinositide-3-kinase: the lipids take center stage. Current Opinion in Cell Biology, 11, 219.
46. Levitzki A. (1996) Targeting signal transduction for disease therapy. Current Opinion in Cell Biology, 8, 239.
47. Ludescher C., Eisterer W., Hilbe W., Hofmann J., Thaler J. (1995) Decreased potency of MDR-modulators under serum conditions determined by fucntional assay. British Journal of Haematology, 91, 652.
48. Luttrell L.M., Daaka Y., Lefkowitz R.J. (1999) Regulation of tyrosine kinase cascade by G-protein-coupled receptors. Current Opinion in Cell Biology, 11, 177.
49. Marshall J.C. (1996) Ras effectors. Current Opinion in Cell Biology, 8, 197.
50. Matter A., Meyer T., Caravatti C., Fabbro D., Mett H., Koizumi S., Geissler J., Lydon N, Traxler P., Regenass U. (1990) A pharmacological approach to growth regulation of breast cancer cells. In The Therapeutic Implications of the Molecular Biology of Breast Cancer. Lippman M.E., Mihich E. (eds), p. 227. John Libbey CIC: Trento.
51. Marte B.M., Meyer T., Stabel S., Jaken S., Fabbro D., Hynes N.E. (1994) Protein kinase C and mammary cell differentiation: an essential role for PKC-α in the induction of β-casein expression. Cell Growth and Differentiation, 5, 239.
52. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., Lemischka I.R. (1991) A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proceedings of the National Academy of Sciences, USA, 88, 9026.
53. McDonald A.C., Propper D., King D., Champain K., Graf P., Man A. (1997) Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase. Proceedings of the American Society for Clinical Oncology, 16, 212a.
54. Meggio F., Donella Deana A., Ruzzene M., Brunati A.M., Cesaro L., Guerra B., Meyer T., Mett H., Fabbro D., Furet P., Dobrowolska A., Pinna L.A. (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. European Journal of Biochemistry, 234, 317.
55. Mercurio F., Manning A.M. (1999) Mutiple signaling converging on NF-kB. Current Opinion in Cell Biology, 11, 226.
56. Meyer T., Regenass U., Fabbro D., Alteri E., Rösel J., Müller M., Caravatti G., Matter A. (1989) A derivative of staurosporine (PKC412) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo antitumour activity. International Journal of Cancer, 43, 851.
57. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ullrich A. (1993) High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835.
58. Miyamoto K., Inoko K., Wakusawa S., Kajita J., Hasegawa T., Takagi A., Koyama M. (1993) Inhibition of multidrug resistance by a staurosporine derivative, NA-382, in vitro and in vivo. Cancer Research, 53, 1555.
59. Molenaar W.H., Kraneburg O., Postma F.R., Zondag G.C.M. (1997) Lysophosphatidic acid: G-ptotein signalling and cellular reponses. Current Opinion in Cell Biology, 9, 168.
60. Neel B.G., Tonks N.K. (1997) Protein tyrosine phosphatases in signal transduction. Current Opinion in Cell Biology, 9, 193.
61. Norris J.G., Tang L.P., Sparacio S.M., Benveniste E.N. (1994) Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumour necrosis factor-alpha. Journal of Immunology, 152, 841.
62. Parker P.J., Dekker L. (eds) (1997) Protein Kinase C. Landes: Austin, TX.
63. Pastan I., Gottesman M.M. (1991) Multidrug resistance. Annual Review of Medicine, 41, 277.
64. Perletti G.P., Monti E. (1996) PKCs: transducers of critical signals in cancer cells. International Journal of Oncology, 9, 171.
65. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Research, 53, 5822.
66. Pruschy M., Zaugg K., Resch H., Shi Y.Q., Oehler C., Fabbro D., Glanzmann C., Bodis S. (1998) Cooperative cytotoxicity of ionizing radiation and protein kinase C-inhibition in p53 deficient tumor cells. Radiotherapy and Oncology, 48 (suppl. 1), S183, No. 723.
67. Risau W. (1997) Mechanisms of angiogenesis. Nature, 386, 671.
68. Robinson G.S., Pierce E.A., Rook S.L., Foley E., Webb R., Smith L.E. (1996) Oligonucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proceedings of the National Academy of Sciences, USA, 93, 4851.
69. Robinson M.J., Cobb M.H. (1997) Mitogen-activated protein kinase pathways. Current Opinion in Cell Biology, 9, 180.
70. Sampson E., Wolff C.L., Abraham I. (1993) Staurosporine reduces P-glycoprotein expression and modulates MDR. Cancer Letters, 68, 7.
71. Sanford M.S., Schindler M. (1994) Cell biological mechanisms of multidrug resistance in tumours. Proceedings of the National Academy of Sciences, USA, 91, 3497.
72. Sato W., Yusa K., Naito M., Tsuruo T. (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochemical and Biophysical Research Communications, 173, 1252.
73. Seo M.S., Kwak N., Ozaki H., Yamada H., Okamoto N.,Yamada E., Fabbro D., Hofmann F., Wood J.M., Campochiaro P.A. (1999) Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. American Journal of Pathology, 154, 1743.
74. Schwartz G.K. (1996) Protein kinase C inhibitors as inducers of apoptosis for cancer therapy. Expert Opinion in Investigative Drugs, 5, 1601.
75. Schwartz M.A., Baron V. (1999) Interactions between mitogenic stimuli, or, thousand and one connections. Current Opinion in Cell Biology, 11, 197.
76. Sedlak J., Hunakova L., Dutaj J., Chorvath B., Novotny L. (1995) Effects of protein kinase C inhibitor, Staurosporine derivative PKC412, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anticancer Drugs, 6, 70.
77. Shapira L., Takashiba T., Champagne C., Amar S., Van Dyke T.E. (1994) Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes. Journal of Immunology, 153, 181.
78. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene, 5, 519.
79. Shustik C., Dalton W., Gros P. (1995) P-glycoprotein-mediated multidrug resistance in tumour cells: biochemistry, clinical relevance and modulation. Molecular Aspects of Medicine, 16, 1.
80. Smith L.E., Kopchick J.J., Chen W, Knapp J., Kinose F., Daley D., Foley E., Smith R.G., Schaeffer J.M. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science, 276, 1706.
81. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., Shows T.B. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 6, 1677.
82. Thavasu P., Propper D., MacDonald A., Dobbs N., Man A., Harris A., Fabbro D., Balkwill F. (1999) Measurement of biologic response to PKC inhibitor CPG41251 in patients with advanced cancer. Cancer Research, 59, 3980.
83. Thieme H., Aiello L.P., Takagi H., Ferrara N., King G.L. (1995) Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes, 44, 98.
84. Usui T., Yoshida M., Abe K., Osada H., Isono K., Beppu T. (1991) Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. Japanese Journal of Cell Biology, 115, 1275.
85. Utz I., Hofer S., Regenass U., Hilbe W., Thaler J., Grunicke H., Hofmann J. (1994) The protein kinase C inhibitor PKC412: a staurosporine derivative with antitumour activity, reverses multidrug resistance. International Journal of Cancer, 51, 104.
86. Utz I., Spitaler M., Rybczynska M., Ludescher C., Hilbe W., Regenass U., Grunicke H., Hofmann J. (1998) Reversal of multidrug resistance by staurosporine derivatives PKC412. International Journal of Cancer, 77, 64.
87. Virchis A.E., Ganeshaguru K., Prentice H.G., Yong K.-L., Man A., Csermak K. (1998) Results of an exploratory phase II study on a protein kinase C inhibitor in low grade lymphoproliferative disorders. British Journal of Haematology, 102, 192.
88. Yoshiji H., Kuiyama S., Ways K., Yoshiji J., Miyamoto Y., Kawata M., Ikenaka Y., Tsujinoue H., Nakatani T., Shibuya M., Fukui H. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Research, 59, 4413.
89. Zaugg K., Resch H., Hegyi I., Glanzmann C., Fabbro D., Bodis S., Pruschy M. (1999) Cooperative in vivo cytotoxicity of ionizing radiation and the protein kinase C-inhibitor PKC412 in p53-deficient, radioresistant tumor cells. European Journal of Cancer (suppl. 34S181), Abstract No. 689 PR-59.